...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of dermatology >Guide for medical professionals (i.e. dermatologists) for the management of Rhododenol-induced leukoderma
【24h】

Guide for medical professionals (i.e. dermatologists) for the management of Rhododenol-induced leukoderma

机译：医学专家（即皮肤科医生）处理杜鹃醇诱发的白斑病的指南

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Because some users develop depigmentation after the use of melanogenesis-inhibiting products containing the quasi-drug ingredient Rhododenol, Japanese Dermatological Association (JDA) established a Special Committee on the Safety of Cosmetics Containing Rhododenol on July 17, 2013 and management guide for dermatologists has been updated on the website in order to delineate the diagnostic criteria for Rhododenol-induced leukoderma and provides a broad guide for standard treatment based on current knowledge. This guide is produced on the basis of the guide (version 7) updated on June 20, 2014 in the website. Rhododenol-induced leukoderma refers to depigmentation of varying severity that develops after the use of cosmetics containing Rhododenol, mainly at the site of use. In most cases, repigmentation of part or all the affected area is evident after discontinuation. Histopathologically cellular infiltration around the hair follicles and melanophages are present in most cases. The number of melanocytes in the lesion is declined but not totally absent in most cases. Rhododenol itself is a good substrate for tyrosinase, resulting in the formation of Rhododenol metabolites (e.g., Rhododenol quinone). Melanocytes are damaged by Rhododenol metabolites during the subsequent metabolic process. The continued use of cosmetics containing Rhododenol thus induces tyrosinase activity-dependent cytotoxicity in melanocytes in the epidermis at application sites, resulting in decreasing the amount of melanin produced by melanocytes; the addition of some other factor to this process is believed to subsequently cause the decrease or disappearance of melanocytes themselves from the epidermis.
机译：由于某些使用者在使用含有准药物成分杜鹃醇的抑制黑色素生成的产品后会出现脱色现象，因此，日本皮肤病学协会（JDA）于2013年7月17日成立了含有杜鹃醇的化妆品安全性特别委员会，皮肤科医生的管理指南已经制定在网站上进行了更新，以描绘出杜鹃醇诱发的白皮病的诊断标准，并根据当前知识为标准治疗提供了广泛的指南。本指南是根据2014年6月20日在网站上更新的指南（第7版）制作的。杜鹃花醇诱导的白斑病是指在使用含杜鹃花醇的化妆品后，主要在使用部位出现的不同严重程度的脱色。在大多数情况下，停药后很明显部分或全部受影响的区域都已重新着色。在大多数情况下，在毛囊和黑色素细胞周围存在组织病理学上的细胞浸润。在大多数情况下，病变中的黑素细胞数量减少，但并非完全不存在。 Rhododenol本身是酪氨酸酶的良好底物，可导致Rhododenol代谢产物（例如Rhododenol醌）的形成。黑色素细胞在随后的代谢过程中被杜鹃醇代谢物破坏。因此，继续使用含杜鹃醇的化妆品会在施用部位的表皮中的黑色素细胞中诱导酪氨酸酶活性依赖性细胞毒性，从而导致黑色素细胞产生的黑色素减少。据认为，向该过程中添加一些其他因素随后会导致黑素细胞自身从表皮中减少或消失。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号